| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 09/20/2001 | WO2001067883A1 Digestable chewing gum |
| 09/20/2001 | WO2001041567A8 Deep penetrating antimicrobial compositions |
| 09/20/2001 | WO2001034591A3 Substituted 4h-chromene and analogs as activators of caspases and inducers of apoptosis and the use thereof |
| 09/20/2001 | WO2001032180A3 Composition for treatment of constipation and irritable bowel syndrome |
| 09/20/2001 | WO2001015664A3 Coformulation methods and their products |
| 09/20/2001 | WO2001013887A3 Phospholipin gel |
| 09/20/2001 | WO2001007065B1 PRODUCTION OF rhPBGD AND NEW THERAPEUTIC METHODS FOR TREATING PATIENTS WITH ACUTE INTERMITTENT PORPHYRIA (AIP) AND OTHER PORPHYRIC DISEASES |
| 09/20/2001 | US20010023287 Induction of endhotelial procoagulant is inhibited and induction of fibrin deposition is enhanced; cytotoxicity and receptor binding activities unaffected; monoclonal antibody |
| 09/20/2001 | US20010023261 Novel composition for the transdermal administration of drugs |
| 09/20/2001 | US20010023240 Compounds and compositions for delivering active agents |
| 09/20/2001 | US20010022975 Topical gel; containing vasodilator |
| 09/20/2001 | US20010022973 Pharmaceutical composition for piperidinoalkanol compounds |
| 09/20/2001 | US20010022972 Acrylic enteric coating compositions |
| 09/20/2001 | US20010022970 Halogenated xanthan compound |
| 09/20/2001 | US20010022964 Fast dissolving orally consumable films |
| 09/20/2001 | DE10013286A1 New human humanized antibody that specifically binds to fibroblasts activating protein alpha, useful for treating cancer or tumor, and for imaging tumors associated with activated stromal fibroblasts, e.g. lung or breast cancer |
| 09/20/2001 | DE10013259A1 New stable complexes of acesulfame with trace elements e.g. zinc or copper, useful as taste-masked form of trace elements for use in foods, feedstuffs, pharmaceuticals or cosmetics |
| 09/20/2001 | DE10013122A1 New anaesthetic for epidural administration comprises liposomes containing a lipophilic gas, especially xenon |
| 09/20/2001 | DE10013029A1 Multilayer formulation for controlled drug release in colon, comprising drug-containing core having inner and outer coatings of acrylic copolymers with quaternary ammonium and anionic groups respectively |
| 09/20/2001 | DE10012732A1 Thrombin composition, for use as hemostatic or as a component of fibrin glues, comprises non-covalently bonded inhibitor for stabilization |
| 09/20/2001 | DE10012408A1 Verwendung von Lichtschutzmittelkombinationen, die als wesentlichen Bestandteil aminosubstituierte Hydroxybenzophenone enthalten als photostabile UV-Filter in kosmetischen und pharmazeutischen Zubereitungen Use of sunscreen combinations, the amino-substituted hydroxybenzophenones as an essential constituent contain as photostable UV filters in cosmetic and pharmaceutical preparations |
| 09/20/2001 | DE10012063A1 Soft plasticizer-free capsules for use in pharmaceuticals, cosmetics, detergents or plant protectants are made from a polymers obtained by polymerizing a vinyl ester in presence of a polyether substrate |
| 09/20/2001 | DE10011447A1 New stable (meth)acrylate copolymer emulsion containing nonionic emulsifier, useful as coating and binding agent for medicaments, is not subject to emulsifier crystallization |
| 09/20/2001 | CA2403241A1 Pharmaceutical compositions of glycogen phosphorylase inhibitors |
| 09/20/2001 | CA2403233A1 Glycogen phosphorylase inhibitor |
| 09/20/2001 | CA2403084A1 A method for reversing the immunosuppressive effects of the melanoma inhibitory activity "mia" |
| 09/20/2001 | CA2402935A1 Adjuvant for vaccines |
| 09/20/2001 | CA2402865A1 Opioid formulations |
| 09/20/2001 | CA2402645A1 Modulation of cardiovascular injury |
| 09/20/2001 | CA2402547A1 Digestable chewing gum |
| 09/20/2001 | CA2402327A1 Peptides targeting specifically tumor-derived endothelial cells |
| 09/20/2001 | CA2402296A1 Intradermal-penetration agents for topical local anesthetic administration |
| 09/20/2001 | CA2402294A1 Immunomodulatory formulations and methods for use thereof |
| 09/20/2001 | CA2402025A1 Nystatin formulation having reduced toxicity |
| 09/20/2001 | CA2401873A1 Peptidase-cleavable, targeted antineoplastic drugs and their therapeutic use |
| 09/20/2001 | CA2401252A1 Human and humanized fap-alpha-specific antibodies |
| 09/20/2001 | CA2378464A1 Fading inhibitors |
| 09/19/2001 | EP1134223A2 Acesulfam metal complexes, their preparation and use |
| 09/19/2001 | EP1133997A2 Treatment of immune diseases with beta-interferon |
| 09/19/2001 | EP1133994A1 A method for reversing the immunosuppressive effects of the Melanoma Inhibitory Activity "MIA" |
| 09/19/2001 | EP1133989A2 Polymer compositions for use in therapy |
| 09/19/2001 | EP1133985A1 Pressure-sensitive adhesive gel composition for iontophoresis and apparatus therefor |
| 09/19/2001 | EP1133984A1 Solid preparation containing low-substituted hydroxypropyl cellulose and production process thereof |
| 09/19/2001 | EP1133983A2 Self-foaming cleansing systems |
| 09/19/2001 | EP1133980A2 Use of combinations of photoprotectors comprising as essential components aminosubstituted hydroxybenzophenones as photostable UV-filters in cosmetic and pharmaceutical preparations |
| 09/19/2001 | EP1133553A1 Methods using genetic package display for detecting and identifying protein-protein interactions |
| 09/19/2001 | EP1133517A1 INTRACELLULAR TARGETED DELIVERY OF COMPOUNDS BY 70 kD HEAT SHOCK PROTEIN |
| 09/19/2001 | EP1133319A1 Photosensitizer conjugates for targeting intracellular pathogens |
| 09/19/2001 | EP1133318A1 Supramolecular complexes containing therapeutic agents |
| 09/19/2001 | EP1133317A1 Transport system conjugate |
| 09/19/2001 | EP1133316A1 Formulation of adenovirus for gene therapy |
| 09/19/2001 | EP1133310A2 Artery- and vein-specific proteins and uses therefor |
| 09/19/2001 | EP1133301A1 Anti-asthmatic combinations comprising surface active phospholipids |
| 09/19/2001 | EP1133298A1 Compositions comprising cefuroxime axetil |
| 09/19/2001 | EP1133285A1 A process for producing particles with a converted amorphous and/or meta-stable crystalline region into crystalline state |
| 09/19/2001 | EP1133284A1 New process |
| 09/19/2001 | EP1133282A1 Taste masking rapid release coating system |
| 09/19/2001 | EP1133281A1 Dispersible phospholipid stabilized microparticles |
| 09/19/2001 | EP1133280A1 Method of preparing stable suspensions of insoluble microparticles |
| 09/19/2001 | EP1133279A1 Method of producing vitamin powders |
| 09/19/2001 | EP1133278A2 Delivery of liposomal-encapsulated antioxidants and applications thereof |
| 09/19/2001 | EP1133277A1 Pharmaceutical aerosol composition containing hfa 227 and hfa 134a |
| 09/19/2001 | EP1133271A1 Method of producing solid dosage forms |
| 09/19/2001 | EP1112750A9 Drug composition for topical administration |
| 09/19/2001 | EP0918536B1 Composition comprising insulin and insulin-like growth factor-i (igf-i) |
| 09/19/2001 | EP0871434B1 Modified release oral pharmaceutical composition containing 5-asa and method for the treatment of bowel diseases |
| 09/19/2001 | EP0871420B1 Triacetin as a transdermal penetration enhancer |
| 09/19/2001 | EP0789584B1 Application of superoxide dismutase in liposomes |
| 09/19/2001 | EP0600062B1 Polymer-bound paclitaxel derivatives |
| 09/19/2001 | EP0591369B1 Capsid forming and cystein modified chimaeric ms2-coat protein |
| 09/19/2001 | CN1313873A Polyester analogus of poly-L-Lysine as a soluble, biodegradable gene delivery carrier |
| 09/19/2001 | CN1313785A Liquid thickener for surfactant systems |
| 09/19/2001 | CN1313775A Methods and materials for the treatment of prostatic cercinoma |
| 09/19/2001 | CN1313760A Stabilised polyvinylpyrrdidone formulation |
| 09/19/2001 | CN1313759A Fish gelatinous composition for use as an ingredient in tablets |
| 09/19/2001 | CN1313758A Injectable aqueous dispersions of propofol |
| 09/19/2001 | CN1313757A Oral liquid mucoadhesive compositions |
| 09/19/2001 | CN1313756A Oral liquid mucoadhesive compositions |
| 09/19/2001 | CN1313755A Oral mucoadhesive compositions containing gastrointestinal actives |
| 09/19/2001 | CN1313754A Oral liquid mucoadhesive compositions |
| 09/19/2001 | CN1313742A Treatment of female sexual dysfunction |
| 09/19/2001 | CN1313343A N-terminal modified protein compositions and methods therefor |
| 09/19/2001 | CN1071114C Injectable mesna solutions |
| 09/19/2001 | CN1071113C Compositions and processes for the sustained release of drugs |
| 09/19/2001 | CA2372450A1 Liquid injectable formulation of disodium pamidronate |
| 09/18/2001 | US6291671 Reacting organic amine salt of polysaccharide derivative having carboxyl groups with drug compound or spacer bound to compound in nonaqueous system; by-roduct inhibition; drug delivery carriers for antineoplastic/antiinflammatory agents |
| 09/18/2001 | US6291638 Hepatotropic conjugates of antiviral drugs carriers thereof and pharmaceutical compositions containing them |
| 09/18/2001 | US6291582 Polymer-protein composites and methods for their preparation and use |
| 09/18/2001 | US6291462 Oral medicinal preparations with reproducible release of the active ingredient gatifloxacin or its pharmaceutically suitable salts or hydrates |
| 09/18/2001 | US6291440 Iron-dextran compound for use as a component in a therapeutical composition for prophylaxis or treatment of iron-deficiency |
| 09/18/2001 | US6291435 Reduce the virulence of an epec organism, which method comprises contacting an epec organism with a composition comprising a monosaccharide or an oligosaccharide sequence |
| 09/18/2001 | US6291425 Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage |
| 09/18/2001 | US6291423 Lipid complexes for transferring at least a therapeutically active substance, in particular a polynucleotide into a target cell and use in gene therapy |
| 09/18/2001 | US6290996 Administering an extract blend of the fruit of the emblica officinalis plant |
| 09/18/2001 | US6290994 Beverage containing caffeine or theobromine and vinpocetine citrate for stimulating cerebral activity |
| 09/18/2001 | US6290987 Alkali metal alkyl sulfate, at least one membrane mimetic amphiphile, and at least one phospholipid. |
| 09/18/2001 | US6290985 By chewing the gum, the medicament or agent is released from the product. |
| 09/18/2001 | US6290984 Nonaqueous solvent and at least one non-water-soluble alkyl cellulose or hydroxyalkyl cellulose. |
| 09/18/2001 | US6290983 Preparation of biodegradable, biocompatible microparticles containing a biologically active agent |
| 09/18/2001 | US6290981 Use of nitric oxide-releasing agents to treat impotency |